A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice among Chinese NSCLC Patients

Trial Identifier: D5160R00026
Sponsor: AstraZeneca
NCTID:: NCT03485326
Start Date: April 2020
Primary Completion Date: August 2023
Study Completion Date: August 2023
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China, 100142
China Chengde, China
China Chengdu, China, 610041
China Dingzhou, China
China Fuzhou, China
China Ganzhou, China
China Guangzhou, China
China Guangzhou, China, 510010
China Guangzhou, China, 510120
China Guangzhou, China, 510080
China Hangzhou, China
China Hangzhou, China, 310014
China Hangzhou, China, 310003
China Hangzhou, China, 310052
China Hangzhou, China, 321000
China Harbin, China, 150081
China Huanghua, China
China Jinan, China, 2501117
China Linhai, China, 317000
China Nanchang, China
China Shanghai, China, 200052
China Shijiazhuang, China, 050035
China Suzhou, China, 215004
China Taiyuan, China, 030000
China Tianjin, China, 300052
China Weihai, China
China Wuhan, China, 430079
China Wuhan, China, 430030
China Zhuji, China